Background: The prognostic nutritional index (PNI) is an indicator of nutritional immune status.
Introduction
Nutritional immune status is closely related to various aspects of malignant tumors. Previous studies have found that malnutrition and poor immune status might increase the risk of postoperative complications, reduce the response to antitumor therapy, and be related to poor survival (1) (2) (3) (4) .
The prognostic nutritional index (PNI) was initially used to evaluate nutritional status in patients undergoing surgery (5) . Predictive and prognostic value of prognostic nutritional index for locally advanced breast cancer blood lymphocytes (6) . Currently, the PNI has been extended to the field of cancer as an indicator of nutritional immune status and has been found to be significantly associated with the therapeutic effects and long-term prognosis of various solid tumors (7) (8) (9) (10) .
In gastrointestinal tumors, low PNI was an independent poor prognostic factor for patients (7, 8, 10) . Breast cancer is the most common cancer in the world, and seriously endangers women's health (11) . A relatively low PNI was also found to be related to poor clinical outcome of breast cancer (12) . However, fewer breast cancer patients in the early stage or even in the locally advanced stage showed significant malnutrition at the time of diagnosis. Instead, breast cancer might commonly be an overnutritionrelated disease. Obesity is a vital risk factor for breast cancer in postmenopausal women (13) . For breast cancer patients, a higher body mass index (BMI) was related to poor prognosis and resistance to therapy (14, 15) . Previous studies have shown a significant positive correlation between PNI and BMI (16) . Collectively, we hypothesized that an excessively high PNI may be associated with poor chemotherapy response and poor prognosis in breast cancer patients. To test this hypothesis, we retrospectively analyzed the relationship between an excessively high PNI and the treatment efficacy and prognosis of patients with locally advanced breast cancer who received neoadjuvant therapy.
Methods

Patients and treatment
This study was a retrospective analysis based on prospective clinical trials, of SHPD002 (NCT02221999) and SHPD003 (NCT02879513), conducted in Renji Hospital, School of Medicine, Shanghai Jiao Tong University. Forty-five is a widely used cutoff of PNI in the context of gastrointestinal surgery (6) due to the number of studies that regarded a PNI of less than or equal to 45 as low and the fact that low PNI was highly associated with poor prognosis of cancer patients (4, 9) We excluded patients with a PNI less than or equal to 45 and explored the prognostic and predictive value of the PNI above safe surgery cutoff (PNI >45). A total of 251 patients participated in these two clinical trials from October, 2013 to March, 2018. Thirteen patients who did not undergo breast surgery after neoadjuvant therapy were dropped, and five of them were lost to follow-up. Thirty patients who did not have a comprehensive record of complete blood count and albumin within 7 days before the first round of neoadjuvant chemotherapy were excluded. Six patients' PNI values were less than or equal to 45 were also excluded. Thus, 202 patients were analyzed in this study ( Figure 1 ). All patients received weekly paclitaxel with cisplatin for 16 weeks before the surgery. Patients with positive hormone receptors randomly either combined (17) .
Data collection
Basic information which included age, menopausal status, height, weight and tumor information which consisted of tumor stage, estrogen receptor (ER) status, progesterone receptor (PR) status, HER2 receptor status, and ki67 index of the primary tumor before neoadjuvant therapy, was collected. ER and PR expression greater than or equal to 1% was defined as positive and less than 1% was defined as negative. ER or PR positivity was defined as hormone-receptor positive. ER and PR negativity were defined as hormone-receptor negative. FISH amplification or immunohistochemistry of HER2 3+ was defined as HER2 positive. No invasive breast cancer in the breast and no pathological involvement in the axillary lymph nodes were defined as pCR. Blood tests, including serum albumin and total peripheral blood lymphocytes, were performed within 7 days before the first round of neoadjuvant chemotherapy and were recorded to calculate the PNI. The PNI is equal to 10× the serum albumin concentration (g/dL) +0.005× the total lymphocyte count (per mm 3 ). The upper quartiles of all patients' PNI was 55. Thus, the definition of an excessively high PNI was a PNI greater than or equal to 55, and a high PNI was greater than 45 and less than 55.
Statistical methods
The 
Results
Clinicopathologic characteristics
A total of 202 patients were included in the analyses, with a median follow-up of 26 months (IQR, 16-42 months). One hundred forty-seven patients were in the high-PNI group and 55 patients were in the excessively-high-PNI group.
The median Ki67 index was 40% in high-PNI, excessivelyhigh-PNI group and total patients. There were 65 patients who achieved a pCR, and the total pCR rate was 32.18%. In terms of menopausal status (P=0.350), clinical tumor stage (P=0.575), ER status (P=0.189), PR status (P=0.215), HER2 status (P=0.847), the high-PNI and excessively-high-PNI groups were not significantly different ( Table 1) . In addition, ER status (OR =0.152; 95% CI, 0.059-0.389, P<0.001) and HER2 status (OR =4.591; 95% CI, 2.126-9.917, P<0.001) could also predict pCR ( Table 2) .
Association of PNI and pCR
Survival analyses
In the univariate analysis, the DFS of the excessively-high-PNI group was significantly shorter than that of the high-PNI group (log-rank P=0.013, Figure 2 ). Multivariate analysis showed that the PNI was an independent prognostic factor for DFS (HR =3.027; 95% CI, 1.207-7.592, P=0.018, PNI, prognostic nutrition index; ER, estrogen receptors; PR, progesterone receptors; HER2, human epidermal growth factor receptor 2; pCR, pathological complete response. Figure 3 ), the PNI was also significantly related to the DFS of patients.
Discussion
In this study, we evaluated the relationship between the PNI and the treatment sensitivity and prognosis for breast cancer patients who received neoadjuvant chemotherapy.
As far as we know, this was the first time that patients with excessively-high PNI were found to have more difficultly achieving pCR and to have shorter DFS durations. High-PNI Therefore, we propose a new viewpoint that an excessively high PNI is a risk factor for poor treatment efficacy and prognosis for breast cancer patients undergoing neoadjuvant chemotherapy. Given that nutritional immune status of cancer patients has attracted increasing attention, our research has important clinical implications. The PNI is a serum albumin-and peripheral blood lymphocyte-based nutritional parameter (6) . The PNI was initially used to provide an accurate, quantitative estimate of operative risk in individuals undergoing gastrointestinal surgery (5) . Currently, the PNI is a simple indicator that has extensive clinical applications. The relationship between the PNI and prognosis in various types of malignancies was reported previously (4, 10, 16, 18, 19) . Although findings related to the PNI and prognosis have been reported in breast cancer patients (12, 20) , these studies did not focus on the difference between high and excessively high PNI values. Because U-shaped or J-shaped associations have been found between BMI and all-cancer mortality (21, 22) , we postulated that both low PNI and excessively high PNI might predict poor prognosis in breast cancer patients. Fewer patients who were initially diagnosed with breast cancer had a lower PNI. Out of 208 patients with comprehensive records in our study, only 6 patients' PNI was less than or equaled to 45. In contrast to the abovementioned prior research, we excluded patients with low PNI values (PNI ≤45) and divided patients into high-PNI and excessively-high-PNI group. Furthermore, we tested our hypothesis using a prospective follow-up database of locally advanced breast cancer patients in neoadjuvant clinical trials and found that patients with excessively high PNI values had significantly shorter DFS than patients with high PNI values. An excessively high PNI was an independent risk factor for DFS among nonmalnourished neoadjuvant chemotherapy patients. Several studies have found that nutritional status was related to the prognosis of breast cancer (14, 15, 23, 24) . A meta-analysis that included data from 213,075 breast cancer patients in 82 studies (including 23,182 cases of breast cancer-related deaths) suggested that overweight (BMI 25-30, RR =1.07; 95% CI, 1.02-1.12) and obesity (BMI >30, RR =1.41; 95% CI, 1.29-1.53) increased the risk of breast cancer death (24) . In patients who received neoadjuvant therapy, high BMI was associated with worse DFS and overall survival (OS) (23). All these data indirectly supported our results. It was reported that obesity caused chronic inflammation both systemically and locally and promoted breast cancer growth (25, 26) . However, inflammation and its protumor consequences could be found in some individuals who are not considered obese or overweight by BMI (27) . Thus, the PNI is a good complement to BMI for the estimation of the overnutrition status and prognosis of breast cancer patients. Nutritional parameters have been reported to be related to sensitivity to treatment. Previous studies have shown that overnutrition could detrimentally affect treatment outcomes (23) . In the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial, Sestak et al. found that obese patients (BMI >35 kg/m 2 ) had a higher recurrence rate in a group of postmenopausal breast cancer patients treated with anastrozole or tamoxifen. The relative efficacy of anastrozole compared to tamoxifen was greater in the thin postmenopausal women (28) . In terms of neoadjuvant therapy, Fontanella et al. combined data from 8,872 patients in eight neoadjuvant clinical trials of breast cancer and performed an analysis. A BMI >30 kg/m 2 had a negative impact on pCR rate (23) . In our study, we also found that a higher BMI (≥24) might make it more difficult to achieve pCR (P=0.049). The PNI, which combines albumin and lymphocyte count, might reflect nutritional and immune status. A higher PNI might indicate a better nutritional status. Consistent with the BMI results, the patients in our study with an excessively high PNI (>55) had more difficultly to achieve pCR. Our results demonstrated that an excessively high PNI could predict poor treatment response and further explored the meaning of the PNI in the context of breast cancer. In addition, many large prospective neoadjuvant clinical trials have demonstrated that patients who achieved pCR might have a better long-term prognosis (29, 30) . Our study found that patients with an excessively high PNI had more difficultly achieving pCR than patients with a high PNI. Therefore, this finding could partially explain the poor prognosis of patients with an excessively high PNI.
The major strengths of this study were that it was based on neoadjuvant clinical trials and that the follow-up database was perspective. The limitations were the relatively small sample size, the short mean follow-up duration and the current absence of OS results. The OS will be analyses after a longer follow-up. Further validation in a large prospective study is needed to further assess the predictive and prognostic value of PNI for breast cancer patients in the future.
Conclusions
Overall, an excessively high PNI was a risk factor for sensitivity to neoadjuvant therapy and prognosis of patients with locally advanced breast cancer. Large-scale, prospective studies are needed in the future to further validate and optimize the predictive power of the PNI in terms of neoadjuvant chemotherapy for breast cancer.
